(Scale All Share (Ref.), Retail, TPG GR)



Buy EUR 17.50		Value Indicators: DCF: Peer group:	EUR 17.67 25.45	Warburg Risk Score: Balance Sheet Score: Market Liquidity Score:	2.4 3.8 1.0	Description: The Platform Group provide service B2B/B2C e-commer platform	
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2025e
		Market cap:	211	Freefloat	30.00 %	Beta:	1.5
Price	EUR 10.35	No. of shares (m):	20	Dr. Dominik Benner	70.00 %	Price / Book:	1.4 x
Upside	69.1 %	EV:	321	Paladin Asset Management	9.90 %	Equity Ratio:	44 %
оролого	0011 /0	Freefloat MC:	63			Net Fin. Debt / EBITDA:	1.9 x
		Ø Trad. Vol. (30d):	804.53 th			Net Debt / EBITDA:	1.9 x

Significant expansion of pharmacy business planned

Stated Figure	es Q2/2	025:							Comment on Figures:
FY End: 31.12. in EUR m	Q2 25	Q2 25e	Q2 24	yoy	6M 25	6M 25e	6M 24	yoy	 H1 results included first-time consolidation effects of approx. EUR 46m Organic sales growth was strong at 28%, driven especially by the
Sales EBITDA adj. Margin EBITDA Margin	24	178 19 10.9 % 19 10.9 %	124 9 7.3 % 13 10.7 %	47 % 92 % 82 %	44	338 35 10.4 % 39 11.5 %	30	48 % 90 % 45 %	Consumer Goods segment Last year's margins were diluted by the car fleet sell-off from the ViveLaCar acquisition Reported EBITDA includes a badwill effect of EUR 9.4m

The Platform Group published H1 results that were broadly in line with expectations and confirmed its recently raised full-year guidance. H1 sales rose 48% to EUR 343m, slightly above our estimate of EUR 338m. While a notable portion of the increase was driven by first-time consolidations (approx. EUR 46m), organic growth of 28% was still impressive. The increase was mainly driven by the Consumer Goods segment, which grew by 72% yoy (EUR 217m), though all segments achieved double-digit growth.

The gross margin improved notably from 28.5% in H1 24 to 34.1%. This was mainly due to the sell-off of the car fleet from the ViveLaCar acquisition, which diluted last year's margin. The adj. EBITDA margin increased from 7.6% to 9.7%. Reported EBITDA was primarily adjusted for positive bargain effects (EUR 9.4m), however, the total adjustments (EUR 10.4m) were below the positive one-offs in H1 24 (EUR 12.5m). As a result, the reported EBITDA margin of 12.7% remained slightly below last year's figure of 13.0%.

Against this background, TPG confirmed its recently increased full-year guidance, aiming for EUR 715-735m in sales and adj. EBITDA of EUR 54-58m. The implied top-line acceleration, driven by continued strong organic momentum and the first-time consolidation of the new Optics & Hearing segment (WRe EUR 13m) as well as Joli Closet (WRe EUR 5m), appears rather conservative. The expected lower EBITDA margin in H2 reflects the seasonally weaker profitability of the Consumer Goods segment due to sales events such as Black Friday and Christmas promotions. Nevertheless, considering the cautious top-line target, the upper end of the range should be well within reach.


In addition, TPG announced three new targets in Germany, Austria and the Czech Republic to expand its pharmacy business. These targets have a combined annual revenue in the low triple-digit millions and an EBITDA margin of 4-6%. To finance the transaction, which is expected to be in the double-digit millions, the company is considering expanding its bond by up to EUR 20m. Letters of intent were signed earlier this month, with the signing of the transaction expected in September. Given the limited details available, we have not yet included these deals in our model.

In conclusion, TPG delivered strong H1 figures in line with expectations. Given the high organic growth momentum and the additional first-time consolidation effects expected in H2, the recently increased and now confirmed targets appear conservative. In addition, the deal pipeline is well filled with attractive targets and should provide positive news-flow for the rest of the year. We confirm our estimates, our target price and our Buy recommendation for The Platform Group.



FY End: 31.12. in EUR m	CAGR (24-27e)	2021	2022	2023	2024	2025e	2026e	2027e
Sales	20.1 %	241	387	441	525	727	847	910
Change Sales yoy		153.9 %	61.0 %	13.8 %	19.0 %	38.5 %	16.5 %	7.5 %
Gross profit margin		34.3 %	29.8 %	26.1 %	32.2 %	28.3 %	28.2 %	28.3 %
EBITDA	11.6 %	7	37	47	56	59	71	77
Margin		3.1 %	9.5 %	10.8 %	10.6 %	8.1 %	8.3 %	8.5 %
EBITDA adj.	32.5 %	7	12	23	33	55	71	77
Margin		3.1 %	3.1 %	5.1 %	6.3 %	7.6 %	8.3 %	8.5 %
EBIT	11.2 %	2	26	39	46	46	57	63
Margin		0.9 %	6.6 %	8.9 %	8.7 %	6.3 %	6.7 %	6.9 %
Net income	6.2 %	2	19	26	31	25	34	37
EPS	4.6 %	0.30	1.12	1.50	1.60	1.23	1.64	1.83
DPS	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCFPS		-2.89	0.41	3.06	2.56	1.05	0.90	1.72
FCF / Market cap		-10.3 %	5.4 %	55.8 %	33.4 %	10.2 %	8.7 %	16.6 %
EV / Sales		0.9 x	0.6 x	0.4 x	0.5 x	0.4 x	0.4 x	0.3 x
EV / EBITDA		28.2 x	6.2 x	3.4 x	4.5 x	5.5 x	4.3 x	3.5 x
EV / EBIT		92.3 x	8.9 x	4.1 x	5.5 x	7.1 x	5.4 x	4.3 x
P/E		93.7 x	6.7 x	3.6 x	4.8 x	8.4 x	6.3 x	5.7 x
FCF Potential Yield		3.5 %	14.9 %	25.4 %	20.8 %	15.9 %	19.6 %	23.7 %
Net Debt		34	99	69	101	110	92	57
ROCE (NOPAT)		2.9 %	17.0 %	23.4 %	23.2 %	14.1 %	15.5 %	16.2 %
	025: GMV E	UR 1.3bn, sa	les EUR 715	-735m, adj. E	BITDA EUR	54-58m		






Company Background

- The Platform Group offers an e-commerce platform solution, connecting smaller stationary retailers from a wide range of industries to large number of online stores, owned and operated by TPG and third-party websites.
- The Consumer Goods segment comprises B2C platform activities with conventional parcel sizes and is focused on customer as well as sales optimization. The Fashionette business is also included in this BU.
- Business activities in Freight Goods specializes in products with more complex logistic requirements such as furniture retailers, bicycles,
 e-scooters and car-subscription platforms.
- Industrial Goods comprises platforms for new & used machinery, bottling, dental care, barber-shop supplies and car parts. The segment is focused in B2B specific marketing, management, logistics and after-sales service.
- The Service & Retail Goods segment comprises e-commerce services for pharmacies, real-estate businesses and online learning platforms. The 10 legacy stores owned by TPG also contribute to this business unit.

Competitive Quality

- Scalable e-commerce platform for stationary and smaller businesses based on a proprietary software solution, which is not trivial to replicate.
- Large and growing partner and customer base from a diversified spectrum of industries.
- Striving for a cycle of growth by expanding product offering which triggers positive feedback and attracts more consumers, which in turn increases the platform's value.
- Solid margins even compared with larger peers despite tough competition for customers from major online retailers in each industry.
- Pure platform approach limits requirements for capex and working capital





DCF model														
	Detaile	d forecas	t period				7	ransition	al period					Term. Value
Figures in EUR m	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	
Sales	727	847	910	973	1,042	1,109	1,176	1,241	1,303	1,368	1,436	1,486	1,516	
Sales change	38.5 %	16.5 %	7.5 %	7.0 %	7.0 %	6.5 %	6.0 %	5.5 %	5.0 %	5.0 %	5.0 %	3.5 %	2.0 %	2.0 %
EBIT	46	57	63	68	71	72	73	74	76	75	79	82	83	
EBIT-margin	6.3 %	6.7 %	6.9 %	7.0 %	6.8 %	6.5 %	6.2 %	6.0 %	5.8 %	5.5 %	5.5 %	5.5 %	5.5 %	
Tax rate (EBT)	22.0 %	24.0 %	26.0 %	28.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	
NOPAT	36	43	47	49	50	50	51	52	53	53	55	57	58	
Depreciation	13	14	14	16	17	18	19	20	21	22	23	24	24	
in % of Sales	1.8 %	1.7 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	
Changes in provisions	0	0	0	0	0	0	0	0	0	0	0	0	0	
Change in Liquidity from														
- Working Capital	3	19	6	5	-7	-4	1	0	6	6	6	5	3	
- Capex	12	12	13	17	18	19	20	21	22	23	24	24	24	
Capex in % of Sales	1.7 %	1.5 %	1.4 %	1.7 %	1.7 %	1.7 %	1.7 %	1.7 %	1.7 %	1.7 %	1.7 %	1.6 %	1.6 %	
- Other	44	10	62	0	0	0	0	0	0	0	0	0	0	
Free Cash Flow (WACC Model)	-11	16	-19	43	56	53	49	51	46	45	48	53	56	57
PV of FCF	-11	14	-15	31	37	32	27	25	21	19	18	18	17	220
share of PVs		-2.54 %						54.02	2 %					48.52 %

Model parameter				Valuation (m)								
Derivation of WACC:		Derivation of Beta:		Present values 2037e	233							
				Terminal Value	220							
Debt ratio	25.00 %	Financial Strength	1.60	Financial liabilities	114							
Cost of debt (after tax)	6.3 %	Liquidity (share)	1.80	Pension liabilities	0							
Market return	8.25 %	Cyclicality	1.30	Hybrid capital	0							
Risk free rate	2.75 %	Transparency	1.60	Minority interest	0							
		Others	1.40	Market val. of investments	0							
				Liquidity	22	No. of shares (m)	20.4					
WACC	9.99 %	Beta	1.54	Equity Value	361	Value per share (EUR)	17.67					

Jens	itivity va	iue per 311	are (LUIN)													
		Terminal (Growth								Delta EBIT	-margin					
Beta	WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta \	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.78	11.0 %	14.07	14.28	14.50	14.73	14.97	15.23	15.51	1.78	11.0 %	8.19	10.37	12.55	14.73	16.91	19.09	21.26
1.66	10.5 %	15.33	15.58	15.84	16.11	16.40	16.71	17.04	1.66	10.5 %	9.18	11.49	13.80	16.11	18.42	20.73	23.04
1.60	10.2 %	16.02	16.29	16.57	16.87	17.18	17.52	17.88	1.60	10.2 %	9.72	12.10	14.48	16.87	19.25	21.63	24.02
1.54	10.0 %	16.75	17.04	17.34	17.67	18.02	18.39	18.78	1.54	10.0 %	10.29	12.75	15.21	17.67	20.13	22.59	25.05
1.48	9.7 %	17.52	17.83	18.17	18.53	18.91	19.32	19.75	1.48	9.7 %	10.90	13.44	15.98	18.53	21.07	23.61	26.16
1.42	9.5 %	18.34	18.68	19.05	19.44	19.86	20.31	20.79	1.42	9.5 %	11.55	14.18	16.81	19.44	22.07	24.70	27.33
1.30	9.0 %	20.14	20.56	21.00	21.47	21.99	22.54	23.13	1.30	9.0 %	13.00	15.83	18.65	21.47	24.30	27.12	29.95

- Estimated cash outflows for acquisitions are incorporated in the 2025 "Others" line
- Cash flows in the current year were also adjusted in the "Others" line for positive bargain effects already realized
- Cash outflows from TPG's options to buy its minorities is in the 2026 "Others" line
- Since we assume TPG will aquire 100% of most subsidiaries, we have set the value of the minority interest to zero
- IFRS 16 amortisation is adjusted in "Others"; associated lease liabilities are corrected in the net debt




Valuation							
	2021	2022	2023	2024	2025e	2026e	2027e
Price / Book	2.2 x	1.4 x	1.2 x	1.1 x	1.4 x	1.1 x	0.9 x
Book value per share ex intangibles	2.89	-0.11	-1.58	-0.24	-0.05	1.51	3.26
EV / Sales	0.9 x	0.6 x	0.4 x	0.5 x	0.4 x	0.4 x	0.3 x
EV / EBITDA	28.2 x	6.2 x	3.4 x	4.5 x	5.5 x	4.3 x	3.5 x
EV / EBIT	92.3 x	8.9 x	4.1 x	5.5 x	7.1 x	5.4 x	4.3 x
EV / EBIT adj.*	92.3 x	8.9 x	4.1 x	5.5 x	7.1 x	5.4 x	4.3 x
P / FCF	n.a.	18.4 x	1.8 x	3.0 x	9.8 x	11.5 x	6.0 x
P/E	93.7 x	6.7 x	3.6 x	4.8 x	8.4 x	6.3 x	5.7 x
P / E adj.*	93.7 x	6.7 x	3.6 x	4.8 x	8.4 x	6.3 x	5.7 x
Dividend Yield	n.a.						
FCF Potential Yield (on market EV)	3.5 %	14.9 %	25.4 %	20.8 %	15.9 %	19.6 %	23.7 %



Consolidated profit & loss							
In EUR m	2021	2022	2023	2024	2025e	2026e	2027
Sales	241	387	441	525	727	847	91
Change Sales yoy	153.9 %	61.0 %	13.8 %	19.0 %	38.5 %	16.5 %	7.5 9
ncrease / decrease in inventory	0	0	0	0	0	0	
Own work capitalised	2	0	0	0	0	0	
Total Sales	243	387	441	525	727	847	9.
Material expenses	160	272	326	356	521	608	6
Gross profit	83	115	115	169	206	239	2
Gross profit margin	34.3 %	29.8 %	26.1 %	32.2 %	28.3 %	28.2 %	28.3
Personnel expenses	16	27	22	28	40	47	4
Other operating income	18	29	33	29	14	15	
Other operating expenses	77	80	78	114	121	137	1
Jnfrequent items	0	0	0	0	0	0	
EBITDA	7	37	47	56	59	71	
Margin	3.1 %	9.5 %	10.8 %	10.6 %	8.1 %	8.3 %	8.5
Depreciation of fixed assets	2	5	4	4	6	6	
EBITA	5	32	44	51	53	65	
Amortisation of intangible assets	3	7	4	5	7	8	
Goodwill amortisation	0	0	0	0	0	0	
EBIT	2	26	39	46	46	57	
Margin	0.9 %	6.6 %	8.9 %	8.7 %	6.3 %	6.7 %	6.9
EBIT adj.	2	26	39	46	46	57	(
nterest income	0	0	0	0	0	0	
nterest expenses	1	2	6	9	11	10	
Other financial income (loss)	0	0	0	0	0	0	
≣BT	2	25	33	36	35	47	
Margin	0.8 %	6.3 %	7.5 %	6.9 %	4.8 %	5.5 %	5.8
Total taxes	0	0	0	1	8	11	
Net income from continuing operations	2	25	33	36	27	36	
ncome from discontinued operations (net of tax)	0	-3	-6	-3	0	0	
Net income before minorities	2	21	27	33	27	36	
Minority interest	0	2	1	2	2	2	
Net income	2	19	26	31	25	34	
Margin	0.8 %	5.0 %	5.9 %	5.9 %	3.5 %	4.0 %	4.1
Number of shares, average	6	17	17	19	20	20	
EPS	0.30	1.12	1.50	1.60	1.23	1.64	1.
EPS adj.	0.30	1.12	1.50	1.60	1.23	1.64	1.

Guidance: 2025: GMV EUR 1.3bn, sales EUR 715-735m, adj. EBITDA EUR 54-58m


Financial Ratios							
	2021	2022	2023	2024	2025e	2026e	2027e
Total Operating Costs / Sales	97.7 %	90.5 %	89.2 %	89.4 %	91.9 %	91.7 %	91.5 %
Operating Leverage	-0.2 x	17.0 x	3.9 x	0.8 x	0.0 x	1.5 x	1.5 x
EBITDA / Interest expenses	14.2 x	24.0 x	7.3 x	5.9 x	5.5 x	7.0 x	7.6 x
Tax rate (EBT)	5.3 %	-1.1 %	-1.0 %	2.2 %	22.0 %	24.0 %	26.0 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	403,194	515,900	640,650	762,562	748,697	748,697	762,562





Consolidated balance sheet							
In EUR m	2021	2022	2023	2024	2025e	2026e	2027
Assets							
Goodwill and other intangible assets	62	91	108	137	154	156	158
thereof other intangible assets	18	59	64	89	107	109	110
thereof Goodwill	44	32	44	47	47	47	47
Property, plant and equipment	10	8	10	18	30	27	24
Financial assets	0	0	0	5	5	5	į
Other long-term assets	0	0	0	0	0	0	(
Fixed assets	72	99	118	159	189	187	186
Inventories	55	127	92	73	86	106	114
Accounts receivable	25	38	55	51	66	74	7
Liquid assets	8	12	8	22	3	21	56
Other short-term assets	12	13	12	17	17	17	17
Current assets	99	191	167	164	171	218	26
Total Assets	171	290	284	323	360	406	450
Liabilities and shareholders' equity							
Subscribed capital	6	18	18	20	20	20	20
Capital reserve	139	51	41	49	49	49	49
Retained earnings	0	9	12	52	77	110	148
Other equity components	-65	11	10	11	7	7	7
Shareholders' equity	80	89	81	132	153	187	224
Minority interest	1	1	1	3	6	8	10
Total equity	81	91	82	135	159	194	234
Provisions	1	5	3	0	0	0	(
thereof provisions for pensions and similar obligations	0	0	0	0	0	0	(
Financial liabilities (total)	41	111	76	123	113	113	113
Short-term financial liabilities	8	36	37	29	29	29	29
Accounts payable	34	31	41	36	60	70	75
Other liabilities	13	52	82	29	29	29	29
Liabilities	90	199	203	188	202	211	217
Total liabilities and shareholders' equity	171	290	284	323	360	406	450


Financial Ratios							
	2021	2022	2023	2024	2025e	2026e	2027e
Efficiency of Capital Employment							
Operating Assets Turnover	4.4 x	2.7 x	3.8 x	4.9 x	6.0 x	6.2 x	6.5 x
Capital Employed Turnover	2.1 x	2.0 x	2.9 x	2.2 x	2.7 x	3.0 x	3.1 x
ROA	2.6 %	19.6 %	22.0 %	19.6 %	13.3 %	17.9 %	20.1 %
Return on Capital							
ROCE (NOPAT)	2.9 %	17.0 %	23.4 %	23.2 %	14.1 %	15.5 %	16.2 %
ROE	2.5 %	22.9 %	30.5 %	29.3 %	17.7 %	19.7 %	18.2 %
Adj. ROE	2.5 %	22.9 %	30.5 %	29.3 %	17.7 %	19.7 %	18.2 %
Balance sheet quality							
Net Debt	34	99	69	101	110	92	57
Net Financial Debt	34	99	69	101	110	92	57
Net Gearing	41.2 %	109.5 %	83.9 %	74.5 %	69.3 %	47.2 %	24.2 %
Net Fin. Debt / EBITDA	454.9 %	268.0 %	144.4 %	180.8 %	187.4 %	130.0 %	73.2 %
Book Value / Share	12.9	5.2	4.7	6.5	7.5	9.2	11.0
Book value per share ex intangibles	2.9	-0.1	-1.6	-0.2	0.0	1.5	3.3





Consolidated cash flow statement							
In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Net income	2	21	27	33	27	36	39
Depreciation of fixed assets	2	5	4	4	6	6	6
Amortisation of goodwill	0	0	0	0	0	0	0
Amortisation of intangible assets	3	7	4	5	7	8	9
Increase/decrease in long-term provisions	0	0	0	0	0	0	0
Other non-cash income and expenses	0	0	-19	-7	-4	0	0
Cash Flow before NWC change	7	33	16	36	37	50	54
Increase / decrease in inventory	-33	-72	37	19	-12	-20	-8
Increase / decrease in accounts receivable	-17	-13	-17	8	-15	-9	-3
Increase / decrease in accounts payable	26	-3	36	-5	23	10	5
Increase / decrease in other working capital positions	4	70	0	0	0	0	0
Increase / decrease in working capital (total)	-19	-19	55	22	-3	-19	-6
Net cash provided by operating activities [1]	-13	13	71	58	34	31	48
Investments in intangible assets	-1	0	-14	-4	-10	-10	-10
Investments in property, plant and equipment	-4	-6	-5	-4	-2	-3	-3
Payments for acquisitions	-22	-19	-59	-48	-31	0	0
Financial investments	0	6	0	0	0	0	0
Income from asset disposals	0	0	0	0	0	0	0
Net cash provided by investing activities [2]	-27	-31	-77	-57	-43	-12	-13
Change in financial liabilities	15	-3	1	14	-10	0	0
Dividends paid	0	0	0	0	0	0	0
Purchase of own shares	0	0	0	0	0	0	0
Capital measures	0	28	0	0	0	0	0
Other	-1	-2	0	0	0	0	0
Net cash provided by financing activities [3]	14	22	2	13	-10	0	0
Change in liquid funds [1]+[2]+[3]	-26	5	-4	15	-19	18	35
Effects of exchange-rate changes on cash	0	0	0	0	0	0	0
Cash and cash equivalent at end of period	8	12	8	22	3	21	56

Financial Ratios							
	2021	2022	2023	2024	2025e	2026e	2027e
Cash Flow							
FCF	-18	7	53	50	22	18	35
Free Cash Flow / Sales	- 7.5 %	1.8 %	12.0 %	9.5 %	3.0 %	2.2 %	3.9 %
Free Cash Flow Potential	7	34	41	52	51	59	64
Free Cash Flow / Net Profit	-975.4 %	36.1 %	204.3 %	160.1 %	85.5 %	54.6 %	94.1 %
Interest Received / Avg. Cash	1.1 %	4.3 %	0.1 %	0.1 %	2.4 %	2.5 %	0.8 %
Interest Paid / Avg. Debt	2.5 %	2.0 %	6.9 %	9.5 %	9.0 %	9.0 %	9.0 %
Management of Funds							
Investment ratio	2.3 %	1.7 %	4.2 %	1.5 %	1.7 %	1.5 %	1.4 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	106.0 %	56.9 %	230.6 %	82.4 %	90.9 %	87.9 %	88.8 %
Avg. Working Capital / Sales	13.9 %	23.2 %	27.2 %	18.5 %	12.4 %	11.9 %	12.5 %
Trade Debtors / Trade Creditors	72.2 %	122.7 %	133.2 %	140.6 %	110.1 %	106.6 %	103.3 %
Inventory Turnover	2.9 x	2.1 x	3.5 x	4.9 x	6.1 x	5.7 x	5.7 x
Receivables collection period (days)	37	36	45	36	33	32	31
Payables payment period (days)	78	42	46	37	42	42	42
Cash conversion cycle (Days)	84	165	103	73	51	54	53



Source: Warburg Research Source: Warburg Research Source: Warburg Research



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer/htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
The Platform Group	5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A2QEFA1.htm

Total



100

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

<u>"_"</u>	Rating suspended:	The available information currently does not permit an evaluation of the company.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING				
Rating	Number of stocks	% of Universe		
Buy	143	71		
Hold	49	24		
Sell	5	2		
Rating suspended	4	2		


201

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	39	76
Hold	9	18
Sell	1	2
Rating suspended	2	4
Total	51	100

PRICE AND RATING HISTORY THE PLATFORM GROUP AS OF 25.08.2025



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



Head of Researchhrueschmeier@warburg-research.comTechnologymschaumann@warburg-research.comStefan Augustin+49 40 309537-168Oliver Schwarz+49 40 309537-168Cap. Goods, Engineeringsaugustin@warburg-research.comChemicals, Agricultureoschwarz@warburg-research.comChristian Cohrs+49 40 309537-175Simon Stippig+49 40 309537-167Industrials & Transportationccohrs@warburg-research.comReal Estate, Telcosstippig@warburg-research.comDr. Christian Ehmann+49 40 309537-167Marc-René Tonn+49 40 3BioTech, Life Sciencecehmann@warburg-research.comAutomobiles, Car Suppliersmtonn@warburg-research.comFelix Ellmann+49 40 309537-120Robert-Jan van der Horst+49 40 309537-258Software, ITfellmann@warburg-research.comTechnologyrvanderhorst@warburg-research.comMarius Fuhrberg+49 40 309537-258Andreas Wolf+49 40 3Financial Servicesmfuhrberg@warburg-research.comSoftware, ITawolf@warburg-research.comFabio Hölscher+49 40 309537-240Andreas Wolfawolf@warburg-research.comPhilipp Kaiser+49 40 309537-260Feal Estate, ConstructionFeal Estate, Constructionpkaiser@warburg-research.com	309537-250 research.com 309537-265 research.com 309537-259 research.com 309537-290 research.com 309537-140
RESEARCH Henner Rüschmeier Head of Research Head of Research Head of Research hrueschmeier@warburg-research.com Stefan Augustin Cap. Goods, Engineering Christian Cohrs Industrials & Transportation Dr. Christian Ehmann BioTech, Life Science Felix Ellmann Software, IT Software, IT Software, IT Marius Fuhrberg Financial Services Fabio Hölscher Automobiles, Car Suppliers Marius Fuhrberg Financial Services Fholischer Automobiles, Car Suppliers Marius Fuhrberg Fhilipp Kaiser Felix Ellman Fabio Hölscher Automobiles, Car Suppliers Florescarch.com Fabio Hölscher Automobiles, Car Suppliers Florescarch.com Fholischer Felix Ellmann Fabio Hölscher Fabio Hölscher Fabio Hölscher Fabio Hölscher Fabio Hölscher Fabio Forstruction Fabio Forstr	research.com 309537-250 research.com 309537-265 research.com 309537-259 research.com 309537-290 research.com 309537-140
Henner Rüschmeier Head of Research hrueschmeier@warburg-research.com Stefan Augustin Cap. Goods, Engineering Christian Cohrs Industrials & Transportation Dr. Christian Ehmann BioTech, Life Science Felix Ellmann Software, IT Marius Fuhrberg Financial Services Marius Fuhrberg Financial Services Marius Fuhrberg Fabio Hölscher Automobiles, Car Suppliers Meal Estate, Construction Maresearch.com Mean BioTech, Life Science Maresearch.com Mares	research.com 309537-250 research.com 309537-265 research.com 309537-259 research.com 309537-290 research.com 309537-140
Head of Research hrueschmeier@warburg-research.com Stefan Augustin	research.com 309537-250 research.com 309537-265 research.com 309537-259 research.com 309537-290 research.com 309537-140
Cap. Goods, Engineering Christian Cohrs	research.com 309537-265 research.com 309537-259 research.com 309537-290 research.com 309537-140
Industrials & Transportation ccohrs@warburg-research.com Dr. Christian Ehmann	research.com 309537-259 research.com 309537-290 research.com 309537-140
Dr. Christian Ehmann BioTech, Life Science cehmann@warburg-research.com Felix Ellmann Software, IT fellmann@warburg-research.com Automobiles, Car Suppliers mtonn@warburg-research.com Jörg Philipp Frey Retail, Consumer Goods jfrey@warburg-research.com Marius Fuhrberg +49 40 309537-185 Financial Services mfuhrberg@warburg-research.com Fabio Hölscher Automobiles, Car Suppliers https://doi.org/10.1001/10.10	309537-259 research.com 309537-290 research.com 309537-140
BioTech, Life Science cehmann@warburg-research.com Felix Ellmann	research.com 309537-290 research.com 309537-140
Software, IT fellmann@warburg-research.com Jörg Philipp Frey Retail, Consumer Goods firey@warburg-research.com Marius Fuhrberg Financial Services Fabio Hölscher Automobiles, Car Suppliers Philipp Kaiser Real Estate, Construction fellmann@warburg-research.com +49 40 309537-258 Software, IT Software, IT Software, IT awolf@warburg-research.com Software, IT Andreas Wolf Software, IT	research.com 309537-140
Jörg Philipp Frey Retail, Consumer Goods Ijfrey@warburg-research.com Marius Fuhrberg Financial Services Fabio Hölscher Automobiles, Car Suppliers Philipp Kaiser Real Estate, Construction Philipp Kaiser Retail, Consumer Goods Ijfrey@warburg-research.com F49 40 309537-240 Automobiles, Car Suppliers Fabio Hölscher Automobiles, Car Suppliers Philipp Kaiser Real Estate, Construction Philipp Kaiser Real Estate, Construction Philipp Kaiser Retail, Consumer Goods Ijfrey@warburg-research.com Software, IT Software, IT Automobiles, IT Software,	309537-140
Marius Fuhrberg+49 40 309537-185Financial Servicesmfuhrberg@warburg-research.comFabio Hölscher+49 40 309537-240Automobiles, Car Suppliersfhoelscher@warburg-research.comPhilipp Kaiser+49 40 309537-260Real Estate, Constructionpkaiser@warburg-research.com	research.com
Financial Services mfuhrberg@warburg-research.com Fabio Hölscher +49 40 309537-240 Automobiles, Car Suppliers fhoelscher@warburg-research.com Philipp Kaiser +49 40 309537-260 Real Estate, Construction pkaiser@warburg-research.com	
Automobiles, Car Suppliers fhoelscher@warburg-research.com Philipp Kaiser +49 40 309537-260 Real Estate, Construction pkaiser@warburg-research.com	
Real Estate, Construction pkaiser@warburg-research.com	
Thilo Kleibauer +49 40 309537-257	
Retail, Consumer Goods tkleibauer@warburg-research.com	
Hannes Müller +49 40 309537-255 Software, IT hmueller@warburg-research.com	
Andreas Pläsier +49 40 309537-246	
Banks, Financial Services aplaesier@warburg-research.com	
INSTITUTIONAL EQUITY SALES	
Klaus Schilling +49 69 5050-7400	
Head of Equity Sales, Germany kschilling@mmwarburg.com Tim Beckmann +49 40 3282-2665	
United Kingdom tbeckmann@mmwarburg.com	
Jens Buchmüller +49 69 5050-7415	
Scandinavia, Austria jbuchmueller@mmwarburg.com Matthias Fritsch +49 40 3282-2696 Leyan Ilkbahar +49 40	3282-2695
Matthias Fritsch+49 40 3282-2696Leyan Ilkbahar+49 40United Kingdom, Irelandmfritsch@mmwarburg.comRoadshow/Marketinglilkbahar@mm	
Roman Alexander Niklas +49 69 5050-7412 Antonia Möller +49 69	9 5050-7417
Switzerland, Poland, Italy rniklas@mmwarburg.com Roadshow/Marketing amoeller@mm	
	3282-2694
ургаррединиция и при при при при при при при при при п	iwarburg.com
SALES TRADING DESIGNATED SPONSORING	
	3282-2631 warburg.com
	3282-2658
Sales Trading bquast@mmwarburg.com Designated Sponsoring jtreptow@mm	warburg.com
Christian Salomon +49 40 3282-2685 Sales Trading csalomon@mmwarburg.com	
MACRO RESEARCH	
	3282-2439 nwarburg.com
Our research can be found under:	3 2 2
Warburg Research research.mmwarburg.com/en/index.html LSEG ww	vw.lseg.com
-	apitaliq.com
FactSet www.factset.com	
For access please contact:	
	3282-2703
Sales Assistance aschaper@mmwarburg.com Sales Assistance kmuthig@mm	nwarburg.com